Funding for this research was provided by:
Innovative Medicines Initiative (H2020-JTI-IMI2, grant no. 831458)
Received: 22 March 2022
Accepted: 6 July 2022
First Online: 30 July 2022
: The study was approved by the University of Dundee School of Medicine Research Ethics Committee (SMED REC number 20/07, 27th January 2020). All interviewees gave written informed consent to participation; the secondary analysis reported here was conducted in accordance with this consent.
: Not applicable.
: The authors declare research income to their institution from Menarini, IMI, EMA, NIHR HTA, BHF, Amgen, RTI, CSO Scotland, Tenovus Scotland, George Clinical, Sanofi, and HDR UK, University of Oxford, and consultancy income to their institution from AstraZeneca. ISM declares personal consultancy income from AstraZeneca.